The epidemiology of Alzheimer's disease modifiable risk factors and prevention

XX Zhang, Y Tian, ZT Wang, YH Ma, L Tan… - The journal of prevention …, 2021 - Springer
Mild Alzheimer's disease is the leading cause of dementia, accounting for 50–70% of cases.
Alzheimer's disease is an irreversible neurodegenerative disease, which affects daily life …

Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases

NJ Jensen, HZ Wodschow, M Nilsson… - International journal of …, 2020 - mdpi.com
Under normal physiological conditions the brain primarily utilizes glucose for ATP
generation. However, in situations where glucose is sparse, eg, during prolonged fasting …

[HTML][HTML] The brain as an insulin-sensitive metabolic organ

JL Milstein, HA Ferris - Molecular Metabolism, 2021 - Elsevier
Background The brain was once thought of as an insulin-insensitive organ. We now know
that the insulin receptor is present throughout the brain and serves important functions in …

[HTML][HTML] Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment

MR Rizzo, I Di Meo, R Polito, MC Auriemma… - Pharmacological …, 2022 - Elsevier
Gliflozins are a novel class of oral anti-diabetic drugs, acting as inhibitors of sodium-glucose
co-transporters (SGLTs) through the proximal convoluted tubules (PCT) and intestinal …

Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney memory and ageing study

K Samaras, S Makkar, JD Crawford, NA Kochan… - Diabetes …, 2020 - Am Diabetes Assoc
OBJECTIVE Type 2 diabetes (diabetes) is characterized by accelerated cognitive decline
and higher dementia risk. Controversy exists regarding the impact of metformin, which is …

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: data from pooled double‐blind randomized controlled trials and nationwide …

CH Nørgaard, S Friedrich, CT Hansen… - … Research & Clinical …, 2022 - Wiley Online Library
Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like
peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for …

Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia

ML Charpignon, B Vakulenko-Lagun, B Zheng… - Nature …, 2022 - nature.com
Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may
alter dementia onset. Mixed results are emerging from prior observational studies. To …

Diagnostic, prognostic, and mechanistic biomarkers of diabetes mellitus-associated cognitive decline

H Ehtewish, A Arredouani, O El-Agnaf - International journal of molecular …, 2022 - mdpi.com
Cognitive dysfunctions such as mild cognitive impairment (MCI), Alzheimer's disease (AD),
and other forms of dementia are recognized as common comorbidities of type 2 diabetes …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population …

JV Mui, J Zhou, S Lee, KSK Leung, TTL Lee… - Frontiers in …, 2021 - frontiersin.org
Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and
dipeptidyl peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 …

Modulation of brain hyperexcitability: potential new therapeutic approaches in Alzheimer's disease

S Toniolo, A Sen, M Husain - International journal of molecular sciences, 2020 - mdpi.com
People with Alzheimer's disease (AD) have significantly higher rates of subclinical and overt
epileptiform activity. In animal models, oligomeric Aβ amyloid is able to induce neuronal …